Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991907 | 0.88 | CYP1A2 (0.43) | CYP1A2DGAT1PARP15PARP10CYP2C9 | |
| SCHEMBL21991935 | 0.88 | FBP1 (0.41) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL21991305 | 0.84 | DGAT1 (0.49) | CYP3A4DGAT1PARP15PARP10CYP2C9 | |
| SCHEMBL21991917 | 0.84 | DGAT1 (0.39) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL21991238 | 0.82 | PPARA (0.59) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL21991889 | 0.81 | ALDH1A1 (0.48) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL21991884 | 0.79 | SSTR4 (0.48) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL23605917 | 0.79 | GAA (0.52) | CYP1A2CYP3A4TSHRPPARACYP2C9 | |
| SCHEMBL21991541 | 0.76 | PPARA (0.63) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL21992545 | 0.76 | BRD4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885ABCB11 404/4885CYP3A4 681/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | CYP1A2 2919/4885ABCB11 404/4885CYP3A4 681/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885ABCB11 404/4885CYP3A4 681/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885ABCB11 404/4885CYP3A4 681/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885ABCB11 404/4885CYP3A4 681/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885ABCB11 404/4885CYP3A4 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.